Theratechnologies Reports Strong Q1 2025 Growth

Theratechnologies ( (THTX) ) has released its Q1 earnings. Here is a breakdown of the information Theratechnologies presented to its investors.

Theratechnologies Inc. is a commercial-stage biopharmaceutical company specializing in innovative therapies, notably in the HIV treatment sector, with a focus on redefining standards of care.

In its first quarter of 2025, Theratechnologies reported a revenue growth of 17% year-over-year, reaching $19 million, alongside a net profit of $117,000. The company also highlighted significant regulatory achievements, including FDA approval for its new EGRIFTA WR™ formulation.

Key financial metrics for the quarter included a 44.8% increase in EGRIFTA SV® sales, while Trogarzo® sales saw a decline of 22.4% due to increased competition. The company successfully navigated a temporary supply disruption, which impacted revenues but was mitigated by strategic inventory management. Additionally, Theratechnologies achieved an adjusted EBITDA of $2.3 million, reflecting improved operational performance.

Looking ahead, Theratechnologies anticipates continued growth driven by its HIV portfolio, particularly with the recent approval of EGRIFTA WR™. The company projects fiscal year 2025 revenues between $80 million and $83 million, with adjusted EBITDA expected to range from $10 million to $12 million.